New combo therapy aims to control multiple myeloma after first return
NCT ID NCT06252792
First seen Apr 06, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study looks at a combination of three drugs—daratumumab, pomalidomide, and dexamethasone (Dara-PD)—for people whose multiple myeloma has come back for the first time. The goal is to see how well this treatment controls the disease and delays further progression. About 50 adults aged 18 and older will take part, and researchers will compare results with other standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.